Back
Open Access

Novel strategies to lower Lp(a) What are the emerging insights & therapies?

Session: Lp(a), a new lipid frontier in CV risk management & target for therapy
Topic: Lipids
Speaker: Professor S. Tsimikas (San Diego, US)
Organised by PACE-CME, supported by Novartis and Sanofi in the form of an educational grant
Event: ESC Congress 2020

Congress Presentation

About the speaker

Professor Sotirios Tsimikas

University of California San Diego, San Diego (United States of America)
6 presentations
0 follower

4 more presentations in this session

Lp(a): The new kid in lipid management

Speaker: Professor E. Stroes (Amsterdam, NL)

Access
Video
Thumbnail

Lp(a) as target in cardiovascular prevention: Why worry and how to assess?

Speaker: Professor P. Kamstrup (Herlev, DK)

Access
Video
Thumbnail

ASCVD risk reduction for patients with high Lp(a) in 2020: is there a role for PCSK9 inhibition?

Speaker: Professor V. Bittner (Birmingham, US)

Access
Video
Thumbnail

Discussion.

Speaker: Professor E. Stroes (Amsterdam, NL)

Access
Video
Thumbnail

Access the full session

Lp(a), a new lipid frontier in CV risk management & target for therapy

Speakers: Professor S. Tsimikas, Professor E. Stroes, Professor P. Kamstrup, Professor V. Bittner, Professor E. Stroes
Access
Video
Thumbnail

About the event

Image

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb